Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $35.99 in the prior trading day, Royalty Pharma plc (NASDAQ: RPRX) closed at $35.98, down -0.03%. In other words, the price has decreased by -$0.03 from its previous closing price. On the day, 3.4 million shares were traded. RPRX stock price reached its highest trading level at $36.21 during the session, while it also had its lowest trading level at $35.79.
Ratios:
Our goal is to gain a better understanding of RPRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 32.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.33. For the most recent quarter (mrq), Quick Ratio is recorded 1.26 and its Current Ratio is at 1.26. In the meantime, Its Debt-to-Equity ratio is 1.26 whereas as Long-Term Debt/Eq ratio is at 1.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 16, 2025, initiated with a Overweight rating and assigned the stock a target price of $51.
On June 03, 2024, UBS Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $28.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Norden Gregory sold 33,500 shares for $36.23 per share. The transaction valued at 1,213,749 led to the insider holds 194,848 shares of the business.
Norden Gregory bought 33,500 shares of RPRX for $1,213,747 on Aug 11 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RPRX now has a Market Capitalization of 20982601728 and an Enterprise Value of 26087092224. As of this moment, Royalty’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.66, and their Forward P/E ratio for the next fiscal year is 7.02. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.10 while its Price-to-Book (P/B) ratio in mrq is 2.45. Its current Enterprise Value per Revenue stands at 11.316.
Stock Price History:
The Beta on a monthly basis for RPRX is 0.57, which has changed by 0.24887192 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, RPRX has reached a high of $38.00, while it has fallen to a 52-week low of $24.05. The 50-Day Moving Average of the stock is -0.58%, while the 200-Day Moving Average is calculated to be 12.59%.
Shares Statistics:
The stock has traded on average 3.75M shares per day over the past 3-months and 3163520 shares per day over the last 10 days, according to various share statistics. A total of 432.29M shares are outstanding, with a floating share count of 340.69M. Insiders hold about 21.19% of the company’s shares, while institutions hold 80.40% stake in the company. Shares short for RPRX as of 1755216000 were 14069808 with a Short Ratio of 4.05, compared to 1752537600 on 16733151. Therefore, it implies a Short% of Shares Outstanding of 14069808 and a Short% of Float of 3.3099998.
Earnings Estimates
Royalty Pharma plc (RPRX) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $1.28, with high estimates of $1.41 and low estimates of $1.0.
Analysts are recommending an EPS of between $4.71 and $4.21 for the fiscal current year, implying an average EPS of $4.48. EPS for the following year is $5.11, with 7.0 analysts recommending between $6.2 and $4.46.
Revenue Estimates
4 analysts predict $761.01M in revenue for the current quarter. It ranges from a high estimate of $803M to a low estimate of $723.11M. As of the current estimate, Royalty Pharma plc’s year-ago sales were $735MFor the next quarter, 4 analysts are estimating revenue of $787.53M. There is a high estimate of $831.63M for the next quarter, whereas the lowest estimate is $769M.
A total of 5 analysts have provided revenue estimates for RPRX’s current fiscal year. The highest revenue estimate was $3.16B, while the lowest revenue estimate was $3.02B, resulting in an average revenue estimate of $3.11B. In the same quarter a year ago, actual revenue was $2.8BBased on 5 analysts’ estimates, the company’s revenue will be $3.28B in the next fiscal year. The high estimate is $3.5B and the low estimate is $3.16B.
